Bain Capital

HealthEdge is a technology company that provides an integrated software platform designed for healthcare payors. Founded in December 2004 by Albert Waxman and Rob Gillette, HealthEdge specializes in delivering innovative solutions that help health insurers enhance operational efficiency, improve patient outcomes, and significantly lower administrative costs. The company's flagship product suite, HealthRules, is built on patented technology and can be deployed via the HealthEdge Cloud or on-premises. This platform encompasses various functionalities, including claims and benefits administration, care management, and business intelligence, enabling clients to adopt new business models and streamline processes within the healthcare delivery system. In 2012, HealthEdge expanded its offerings by acquiring Click4Care, which enhanced its capabilities in clinical care management. Headquartered in Burlington, Massachusetts, HealthEdge also has a research and development center in Powell, Ohio.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

CereVasc, Inc. is a medical device company dedicated to developing innovative, minimally invasive treatments for neurological diseases. Founded in 2014 and based in Auburndale, Massachusetts, the company focuses on its flagship product, the eShunt System. This system provides an endovascularly deliverable cerebrospinal fluid shunt along with necessary delivery components, designed to eliminate the need for invasive surgical procedures, general anesthesia, and prolonged hospitalization associated with traditional treatments for communicating hydrocephalus. By offering a less invasive option, the eShunt System aims to enhance patient outcomes and reduce the overall costs of surgical interventions for this serious condition.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Alkeus Pharmaceuticals is a Boston-based clinical-stage biopharmaceutical company dedicated to developing treatments for serious and untreatable ophthalmic conditions. The company's primary focus is on its lead drug candidate, an orally delivered compound aimed at addressing Stargardt disease and age-related macular degeneration. This innovative treatment has the potential to help medical professionals manage symptoms of irreversible vision loss early in life, offering hope to patients affected by these debilitating eye diseases.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Oort is an identity threat detection and response platform that focuses on enhancing enterprise security. Given that over 60% of security breaches involve the misuse of valid identity credentials, Oort recognizes identity as a critical perimeter that cannot be solely defended by personnel. The platform empowers cybersecurity and IT professionals to effectively manage their identity and access management (IAM) programs, providing full visibility and control over their identity attack surface. Oort's SaaS solution is designed for rapid deployment, allowing organizations to quickly reduce identity vulnerabilities at scale. Additionally, it offers network solutions through a network of globally distributed data centers, ensuring robust security for the digital supply chain. Based in Boston, MA, Oort operates as a fully remote startup and is supported by prominent investors such as Bain Capital Ventures, 645 Ventures, and First Star Ventures.

Oort is an identity threat detection and response platform that focuses on enhancing enterprise security. Given that over 60% of security breaches involve the misuse of valid identity credentials, Oort recognizes identity as a critical perimeter that cannot be solely defended by personnel. The platform empowers cybersecurity and IT professionals to effectively manage their identity and access management (IAM) programs, providing full visibility and control over their identity attack surface. Oort's SaaS solution is designed for rapid deployment, allowing organizations to quickly reduce identity vulnerabilities at scale. Additionally, it offers network solutions through a network of globally distributed data centers, ensuring robust security for the digital supply chain. Based in Boston, MA, Oort operates as a fully remote startup and is supported by prominent investors such as Bain Capital Ventures, 645 Ventures, and First Star Ventures.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

HYCU is a leading provider of multi-cloud and SaaS data protection services, specializing in data backup and recovery solutions for on-premises, cloud-native, and SaaS environments. The company's R-Cloud platform streamlines data protection, migration, disaster recovery, and ransomware protection, addressing the complexities and costs associated with traditional data management solutions. By offering a comprehensive and user-friendly approach, HYCU aims to simplify the data monitoring and protection process for multi-cloud data centers. With a strong commitment to customer satisfaction, reflected in an impressive Net Promoter Score, HYCU has established itself as a trusted partner for thousands of companies worldwide. The company is headquartered in Boston, Massachusetts, and has secured significant venture capital funding to support its growth and innovation in the data protection landscape.

Hometap is a fintech company founded in 2018 and based in Boston, Massachusetts, that specializes in home equity investments. It offers homeowners a unique opportunity to access cash without incurring debt or selling their property. By providing immediate funds in exchange for a percentage of the home's future value, Hometap enables homeowners to utilize the money for various purposes, such as paying off debt or financing renovations. This approach allows homeowners to improve their financial situation without the burden of monthly payments or additional loans.

Bain Capital, established in 1984, is a global multi-asset alternative investment firm with over $100 billion in assets under management. Headquartered in Boston, Massachusetts, the firm operates through several business units: Private Equity, Public Equity, Credit, and Venture Capital. Bain Capital Private Equity invests in various sectors, including consumer, healthcare, industrials, and technology, across North America, Europe, and Asia. Bain Capital Ventures, the venture capital arm, focuses on seed to growth-stage investments in enterprise software, infrastructure software, and industries being transformed by data. Bain Capital Life Sciences, a dedicated life sciences investment platform, invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Bain Capital Double Impact, the firm's impact investing arm, builds great companies that deliver both competitive financial returns and meaningful, measurable social and environmental good.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

ConvenientMD LLC is an urgent care provider that offers a wide range of medical services for non-life-threatening injuries and illnesses. Established in 2011 and headquartered in Portsmouth, New Hampshire, the company caters to patients seeking treatment for conditions such as sprains, fractures, cuts, colds, bronchitis, and urinary tract infections. Additionally, ConvenientMD provides preventive care services, including physicals, immunizations, and on-site prescriptions, as well as X-ray and lab services. Patients can access care without appointments from 8 am to 8 pm, seven days a week, with the expectation of being treated within an hour. The organization emphasizes quality care and customer service, employing a fully equipped medical team at its locations across New Hampshire, Maine, and Massachusetts, with plans for further expansion in New England.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

HYCU is a leading provider of multi-cloud and SaaS data protection services, specializing in data backup and recovery solutions for on-premises, cloud-native, and SaaS environments. The company's R-Cloud platform streamlines data protection, migration, disaster recovery, and ransomware protection, addressing the complexities and costs associated with traditional data management solutions. By offering a comprehensive and user-friendly approach, HYCU aims to simplify the data monitoring and protection process for multi-cloud data centers. With a strong commitment to customer satisfaction, reflected in an impressive Net Promoter Score, HYCU has established itself as a trusted partner for thousands of companies worldwide. The company is headquartered in Boston, Massachusetts, and has secured significant venture capital funding to support its growth and innovation in the data protection landscape.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Hi Marley, Inc. is an innovative company based in Boston, Massachusetts, that specializes in enhancing communication within the insurance industry. Founded in 2017, it offers a platform named Marley, which integrates intelligent messaging with a human touch to facilitate seamless interactions between insurance companies and their customers. The platform enables insurers to efficiently manage conversations related to claims, underwriting, and policyholder services, ensuring that customers receive timely updates and responses to their inquiries. By bridging communication gaps, Hi Marley aims to improve customer satisfaction and streamline operations for auto, home, and business insurance providers.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

TeachTown Inc. specializes in developing educational solutions for children diagnosed with autism spectrum disorder, developmental disabilities, intellectual disabilities, and emotional and behavioral disorders. The company's flagship products include TeachTown Basics, a computer-assisted instructional program that combines engaging computer lessons with motivating off-computer activities, and TeachTown Social Skills, an online curriculum that utilizes character-based video modeling to enhance social skills in elementary and middle school children. Additionally, TeachTown provides professional development resources for educators, enabling them to effectively implement its programs in the classroom. With a focus on improving academic, social, and emotional skills, TeachTown serves schools, families, and clinicians, facilitating the educational growth of children with special needs. Founded in 2001 and based in Woburn, Massachusetts, the company has positioned itself as a key resource in the field of special education.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nebulous, Inc. is a Boston-based company founded in 2014 that specializes in developing blockchain hardware and software infrastructure for the decentralized internet. The company is known for its flagship product, Sia, a decentralized cloud storage platform that utilizes blockchain technology to create a marketplace for data storage. Additionally, Nebulous offers Skynet, a decentralized content delivery network (CDN) and file-sharing platform aimed at developers, along with SiaStream, which provides affordable storage solutions for media files to enable fast streaming. As a core contributor and maintainer of the open-source Skynet project, Nebulous plays a significant role in advancing the decentralized web ecosystem.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that focuses on discovering and developing antiviral therapies for severe viral infections. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by SARS-CoV-2. Additionally, Atea is developing several other product candidates, including AT-787, which is in phase 2 trials for hepatitis C, and AT-752 for dengue. Other candidates, such as AT-889 and AT-934, are also in phase 2 clinical trials targeting respiratory syncytial virus. Established in 2014, Atea Pharmaceuticals aims to improve treatment options for patients suffering from serious viral infections.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Hi Marley, Inc. is an innovative company based in Boston, Massachusetts, that specializes in enhancing communication within the insurance industry. Founded in 2017, it offers a platform named Marley, which integrates intelligent messaging with a human touch to facilitate seamless interactions between insurance companies and their customers. The platform enables insurers to efficiently manage conversations related to claims, underwriting, and policyholder services, ensuring that customers receive timely updates and responses to their inquiries. By bridging communication gaps, Hi Marley aims to improve customer satisfaction and streamline operations for auto, home, and business insurance providers.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nebulous, Inc. is a Boston-based company founded in 2014 that specializes in developing blockchain hardware and software infrastructure for the decentralized internet. The company is known for its flagship product, Sia, a decentralized cloud storage platform that utilizes blockchain technology to create a marketplace for data storage. Additionally, Nebulous offers Skynet, a decentralized content delivery network (CDN) and file-sharing platform aimed at developers, along with SiaStream, which provides affordable storage solutions for media files to enable fast streaming. As a core contributor and maintainer of the open-source Skynet project, Nebulous plays a significant role in advancing the decentralized web ecosystem.

TruVideo, Inc. is a company that develops a video and text communication platform tailored for auto repair shops. Founded in 2015 and headquartered in Wellesley, Massachusetts, TruVideo provides an application that enables technicians to record videos showcasing the condition of vehicles and the necessary repairs. This platform allows repair shops to enhance customer engagement by sending personalized video narratives to clients, fostering transparency and trust. Additionally, the service includes mobile payment options, enabling customers to approve repairs and complete payments seamlessly. By offering these tools, TruVideo aims to improve the communication between service providers and their customers, ultimately enhancing the overall experience in the automotive service sector.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Rocket Software, Inc. is a provider of enterprise software solutions that focuses on IT modernization and automation services. Established in 1990 and headquartered in Waltham, Massachusetts, the company offers a wide range of products including application lifecycle management, business intelligence, data migration, enterprise performance management, and mainframe modernization. It serves numerous industries, such as automotive, healthcare, finance, and technology, providing tools and services that help businesses optimize their infrastructure, data, and applications. Additionally, Rocket Software offers training, technical support, and professional services to help clients navigate complex IT challenges and enhance their operational capabilities. With a global presence across North America, Europe, and the Asia-Pacific region, Rocket Software is committed to delivering innovative solutions tailored to meet the evolving needs of its diverse customer base.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

ObserveIT LTD. specializes in insider threat management software solutions aimed at helping organizations identify and mitigate insider threats. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company provides a comprehensive platform that includes insider threat detection, investigation, and prevention tools. Its services encompass data loss detection, user activity monitoring, incident response, and compliance solutions. By offering full playback of security incidents, ObserveIT enables security teams to reduce investigation times significantly and enhance response efficiency. The company's solutions are utilized by over 1,600 global customers across various industries, including financial services, technology, and manufacturing, to secure remote workers and protect against data loss. ObserveIT operates as a subsidiary of Proofpoint, Inc.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

ObserveIT LTD. specializes in insider threat management software solutions aimed at helping organizations identify and mitigate insider threats. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company provides a comprehensive platform that includes insider threat detection, investigation, and prevention tools. Its services encompass data loss detection, user activity monitoring, incident response, and compliance solutions. By offering full playback of security incidents, ObserveIT enables security teams to reduce investigation times significantly and enhance response efficiency. The company's solutions are utilized by over 1,600 global customers across various industries, including financial services, technology, and manufacturing, to secure remote workers and protect against data loss. ObserveIT operates as a subsidiary of Proofpoint, Inc.

Replimune Group, Inc., established in 2015 and based in Woburn, Massachusetts, is a biotechnology company specializing in the development of oncolytic immune-gene therapies for cancer treatment. The company's proprietary Immulytic platform enables the design of product candidates that directly attack cancer cells and stimulate the immune system. Replimune's lead candidate, RP1, is a modified herpes simplex virus currently in Phase I/II trials for various solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, RP2 and RP3 are in early-stage clinical trials, targeting immune checkpoint inhibition and T-cell stimulation, respectively. Replimune aims to rapidly advance these therapies through clinical trials and explore combinations with other immuno-oncology products.

EverTrue, Inc. is a software company based in Boston, Massachusetts, that provides a comprehensive platform designed to enhance fundraising efforts at educational institutions. Founded in 2010, the company connects institutional data with insights from various social and demographic sources, including LinkedIn, Facebook, and the U.S. Census. This integration allows advancement offices to better understand and segment their constituents, identify potential donors, and effectively plan events and trips. EverTrue's suite of products includes solutions for alumni community engagement, online giving, relationship management, and volunteer management, serving over 300 institutions. The platform equips fundraising teams with the necessary tools to engage alumni, raise financial support, and track their progress through improved data accessibility and user-friendly functionalities.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

BevSpot, Inc. is a Boston-based company that develops an online platform designed for the food and beverage industry to manage inventory and streamline operations. Founded in 2014, BevSpot offers a comprehensive food and beverage management software that facilitates inventory management, ordering, invoicing, and access to critical sales data. The cloud-based platform allows users to oversee their entire establishment, from the bar to the kitchen, on any device, ensuring that all data is securely stored in the cloud. This enables businesses in the food and beverage sector to make data-driven decisions, ultimately supporting their growth and operational efficiency.

Semantic Machines, Inc. is focused on developing advanced artificial intelligence technology to enhance human-computer interaction through conversational computing. The company specializes in creating conversational interfaces that enable computers to understand and engage in dialogue with users across various platforms, including speech and text. Their technology encompasses a Conversation Engine for fluid discourse, neural networks for semantic analysis and dialogue management, and speech recognition and synthesis capabilities. Additionally, Semantic Machines employs reinforcement learning to improve system performance over time by learning from user interactions. The company aims to transform customer experiences and reduce costs in sectors such as customer service and home automation. Based in Newton, Massachusetts, with additional offices in Berkeley and Boston, Semantic Machines operates as a subsidiary of Microsoft Corporation.

SevOne, Inc. is a provider of infrastructure performance monitoring and analytics solutions, catering to a global clientele that includes communications service providers, financial services, and large enterprises. Founded in 2003 and headquartered in Boston, Massachusetts, with additional offices in Newark, Delaware, and London, the company focuses on delivering real-time insights through its SevOne Data Platform, which collects and analyzes multi-vendor network performance metrics. Its offerings include customizable visualization tools, network streaming telemetry, and solutions for software-defined networking and SD-WAN monitoring. The patented SevOne Cluster architecture enables rapid monitoring across diverse devices, ensuring that organizations can prevent performance-impacting outages. SevOne's technology is designed to support complex, dynamic infrastructures, helping clients navigate the challenges of next-generation networking. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.

Founded in 1996, Blue Coat is now an industry leader in the field of advanced enterprise security. Originally founded as CacheFlow, the company changed its name to Blue Coat in 2002 to reflect its new emphasis on enterprise security, invoking the image of a baseball umpire’s uniform. In March 2015, Blue Coat was acquired by private equity firm Bain Capital. Blue Coat provides advanced enterprise security for 15,000 organizations across the globe, numbering 88 of the 100 largest global companies among them. The Blue Coat Security Platform provides an integrated platform that addresses companies’ network, security, and cloud requirements. This allows customers a minimal impact on network performance while still providing top-quality protection against advanced threats and improving performance for cloud applications and services. Blue Coat focuses strongly on growth and innovation, with 200 patents issued and pending. Blue Coat also maintains several Research and Development centers across the globe, with facilities in Sunnyvale, California; Draper, Utah; Waterloo, Ontario; Boxborough, Massachusetts; and Lysaker, Norway. The company also providers 24/7 “Follow the Sun” Model Global Support from each of its six support centers. Particularly in recent years, Blue Coat has achieved significant positive recognition within the industry, receiving many awards. Among these accolades are the Frost & Sullivan 2016 Global Network Security Forensics Market Leadership Award; the Frost & Sullivan 2014 Web Security Vendor of the Year Award; the 2015 Cloud Computing Magazine Cloud Computing Excellence Award; and the 2015 Best Cloud Computing Security Solution, Reader Trust Award from SC Magazine.

Turbonomic is a Boston-based software provider specializing in Application Resource Management (ARM) and Network Performance Management (NPM). The company offers AI-powered technology designed to optimize application performance, compliance, and cost in real time. Its hybrid cloud management platform integrates with leading application performance management and IT service management solutions, creating a unified control plane for automating IT resource management. By dynamically adjusting resource supply based on workload demand, Turbonomic enables organizations to maintain optimal application health across on-premises and multi-cloud environments. This capability allows businesses to self-manage their IT resources in real time, ensuring performance while reducing costs.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Rapid7, established in 2000, is a cybersecurity company that offers a range of solutions to help organizations proactively manage their security. Initially focusing on vulnerability management, the company has since expanded its portfolio to include detection and response, security information and event management, cloud security, threat intelligence, application security, and security orchestration, automation, and response. Rapid7 empowers businesses with visibility and insights to make informed security decisions, create action plans, and monitor progress. The company, based in Boston, is committed to helping organizations enhance their security posture and is actively involved in the cybersecurity community.

EverTrue, Inc. is a software company based in Boston, Massachusetts, that provides a comprehensive platform designed to enhance fundraising efforts at educational institutions. Founded in 2010, the company connects institutional data with insights from various social and demographic sources, including LinkedIn, Facebook, and the U.S. Census. This integration allows advancement offices to better understand and segment their constituents, identify potential donors, and effectively plan events and trips. EverTrue's suite of products includes solutions for alumni community engagement, online giving, relationship management, and volunteer management, serving over 300 institutions. The platform equips fundraising teams with the necessary tools to engage alumni, raise financial support, and track their progress through improved data accessibility and user-friendly functionalities.

Manicube is a company focused on enhancing the lives of working women by transforming personal care services. It offers quick and affordable manicure services directly at the workplace, collaborating with corporate HR departments to bring licensed nail technicians to provide 15-minute manicures in convenient locations such as conference rooms or employee service areas. The service caters to busy professionals, allowing them to easily book, modify, and pay for appointments through the Manicube website. Operating in major markets including New York City, Chicago, San Francisco, and Boston, Manicube also extends its offerings to include male grooming services.

ObserveIT LTD. specializes in insider threat management software solutions aimed at helping organizations identify and mitigate insider threats. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company provides a comprehensive platform that includes insider threat detection, investigation, and prevention tools. Its services encompass data loss detection, user activity monitoring, incident response, and compliance solutions. By offering full playback of security incidents, ObserveIT enables security teams to reduce investigation times significantly and enhance response efficiency. The company's solutions are utilized by over 1,600 global customers across various industries, including financial services, technology, and manufacturing, to secure remote workers and protect against data loss. ObserveIT operates as a subsidiary of Proofpoint, Inc.

EverTrue, Inc. is a software company based in Boston, Massachusetts, that provides a comprehensive platform designed to enhance fundraising efforts at educational institutions. Founded in 2010, the company connects institutional data with insights from various social and demographic sources, including LinkedIn, Facebook, and the U.S. Census. This integration allows advancement offices to better understand and segment their constituents, identify potential donors, and effectively plan events and trips. EverTrue's suite of products includes solutions for alumni community engagement, online giving, relationship management, and volunteer management, serving over 300 institutions. The platform equips fundraising teams with the necessary tools to engage alumni, raise financial support, and track their progress through improved data accessibility and user-friendly functionalities.

SevOne, Inc. is a provider of infrastructure performance monitoring and analytics solutions, catering to a global clientele that includes communications service providers, financial services, and large enterprises. Founded in 2003 and headquartered in Boston, Massachusetts, with additional offices in Newark, Delaware, and London, the company focuses on delivering real-time insights through its SevOne Data Platform, which collects and analyzes multi-vendor network performance metrics. Its offerings include customizable visualization tools, network streaming telemetry, and solutions for software-defined networking and SD-WAN monitoring. The patented SevOne Cluster architecture enables rapid monitoring across diverse devices, ensuring that organizations can prevent performance-impacting outages. SevOne's technology is designed to support complex, dynamic infrastructures, helping clients navigate the challenges of next-generation networking. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.

ScaleBase, Inc. is a company that specializes in database scalability, providing a virtual database consolidation layer designed to enhance the performance of application and database infrastructures. Its primary product, the ScaleBase Data Traffic Manager, functions as middleware that manages and balances load between database applications and backend database instances, allowing for dynamic scaling in response to fluctuating business needs. This technology enables organizations to optimize their existing relational databases without requiring any infrastructure changes. ScaleBase serves a diverse clientele, including SaaS companies, online gaming providers, digital media firms, social networks, and enterprises. Founded in 2009 and based in Newton, Massachusetts, ScaleBase operates as a subsidiary of ScaleArc Inc. as of August 2015.

Turbonomic is a Boston-based software provider specializing in Application Resource Management (ARM) and Network Performance Management (NPM). The company offers AI-powered technology designed to optimize application performance, compliance, and cost in real time. Its hybrid cloud management platform integrates with leading application performance management and IT service management solutions, creating a unified control plane for automating IT resource management. By dynamically adjusting resource supply based on workload demand, Turbonomic enables organizations to maintain optimal application health across on-premises and multi-cloud environments. This capability allows businesses to self-manage their IT resources in real time, ensuring performance while reducing costs.

Rapid7, established in 2000, is a cybersecurity company that offers a range of solutions to help organizations proactively manage their security. Initially focusing on vulnerability management, the company has since expanded its portfolio to include detection and response, security information and event management, cloud security, threat intelligence, application security, and security orchestration, automation, and response. Rapid7 empowers businesses with visibility and insights to make informed security decisions, create action plans, and monitor progress. The company, based in Boston, is committed to helping organizations enhance their security posture and is actively involved in the cybersecurity community.

Dynatrace, Inc. is a software intelligence company that offers a comprehensive platform for managing and optimizing enterprise cloud applications. The Dynatrace platform enables users to monitor and analyze their entire IT infrastructure, providing insights into application performance, user experience, and operational efficiency. Its product suite includes tools for monitoring various application environments, such as mobile and web applications, as well as network services. Additionally, Dynatrace provides solutions for real user monitoring and synthetic monitoring to ensure application availability and performance. The platform’s advanced capabilities support customers in modernizing IT operations, accelerating software delivery, and enhancing digital experiences. Dynatrace serves a diverse range of industries, including banking, insurance, retail, and manufacturing, and operates globally with a strong presence in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company is headquartered in Waltham, Massachusetts.

Memento specializes in providing enterprise fraud and compliance solutions tailored for credit unions and community banks in North America and Europe. The company’s flagship platform, Security 4.0, integrates data management, fraud analytics, and case management to enable proactive monitoring and real-time alerts, addressing various technological and regulatory challenges. Memento's offerings include tools for monitoring new account fraud across multiple channels and transaction types, as well as solutions for insider threats and deposit account fraud prevention. Additionally, the company provides a suite of services that help smaller financial institutions meet regulatory requirements and combat identity theft. Established in 2002, Memento is headquartered in Concord, Massachusetts, with additional offices in New York, Los Angeles, Milan, London, and Washington, D.C.

Boston Heart Diagnostics is a healthcare company based in Framingham, Massachusetts, specializing in cardiovascular disease (CVD) management. The company offers a comprehensive suite of medical diagnostics services, including advanced lipid testing, genetic testing, and various laboratory techniques such as gas chromatography and liquid chromatography. Unlike traditional lipid testing providers focused on primary screening, Boston Heart utilizes proprietary testing technology to enable ongoing monitoring of patients' conditions and to identify the most effective pharmaceutical treatments more quickly. This approach allows for personalized treatment options for patients with dyslipidemia, determining the efficacy of lipid-adjusting drugs typically within the first six weeks of treatment, in contrast to the six months required by competing methods. Through its innovative tools and patient support services, Boston Heart aims to enhance disease management for physicians, patients, and pharmaceutical companies.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Rapid7, established in 2000, is a cybersecurity company that offers a range of solutions to help organizations proactively manage their security. Initially focusing on vulnerability management, the company has since expanded its portfolio to include detection and response, security information and event management, cloud security, threat intelligence, application security, and security orchestration, automation, and response. Rapid7 empowers businesses with visibility and insights to make informed security decisions, create action plans, and monitor progress. The company, based in Boston, is committed to helping organizations enhance their security posture and is actively involved in the cybersecurity community.

Enservio is the market leader in property insurance affinity solutions, strategic analytics, and contents software, inventory, valuation, replacement and replacement tools. Enservio created the first SaaS (software as a service) software platform for contents, the first replacement mall, the first payment debit card for claims and the first ContentsITV product. We provide software and services to property insurance carriers and their policy holders nationwide. Founded in 2004, we are headquartered near Boston, in Needham, MA with offices and professional staff across the United States.

Memento specializes in providing enterprise fraud and compliance solutions tailored for credit unions and community banks in North America and Europe. The company’s flagship platform, Security 4.0, integrates data management, fraud analytics, and case management to enable proactive monitoring and real-time alerts, addressing various technological and regulatory challenges. Memento's offerings include tools for monitoring new account fraud across multiple channels and transaction types, as well as solutions for insider threats and deposit account fraud prevention. Additionally, the company provides a suite of services that help smaller financial institutions meet regulatory requirements and combat identity theft. Established in 2002, Memento is headquartered in Concord, Massachusetts, with additional offices in New York, Los Angeles, Milan, London, and Washington, D.C.

Rapid7, established in 2000, is a cybersecurity company that offers a range of solutions to help organizations proactively manage their security. Initially focusing on vulnerability management, the company has since expanded its portfolio to include detection and response, security information and event management, cloud security, threat intelligence, application security, and security orchestration, automation, and response. Rapid7 empowers businesses with visibility and insights to make informed security decisions, create action plans, and monitor progress. The company, based in Boston, is committed to helping organizations enhance their security posture and is actively involved in the cybersecurity community.

Dynatrace, Inc. is a software intelligence company that offers a comprehensive platform for managing and optimizing enterprise cloud applications. The Dynatrace platform enables users to monitor and analyze their entire IT infrastructure, providing insights into application performance, user experience, and operational efficiency. Its product suite includes tools for monitoring various application environments, such as mobile and web applications, as well as network services. Additionally, Dynatrace provides solutions for real user monitoring and synthetic monitoring to ensure application availability and performance. The platform’s advanced capabilities support customers in modernizing IT operations, accelerating software delivery, and enhancing digital experiences. Dynatrace serves a diverse range of industries, including banking, insurance, retail, and manufacturing, and operates globally with a strong presence in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company is headquartered in Waltham, Massachusetts.

Bright Horizons Family Solutions is a prominent provider of early education and childcare services, established in 1986 and headquartered in Newton, Massachusetts. The company specializes in delivering high-quality educational programs, employer-sponsored childcare, backup care, and educational advisory services, all designed to accommodate modern family and work dynamics. Bright Horizons is dedicated to nurturing each child's unique qualities and potential while fostering strong partnerships with families. In collaboration with employers, the company aims to create family-friendly workplaces and promote an environment that encourages professionalism, growth, and diversity. Through its comprehensive offerings, Bright Horizons strives to support the needs of children and families, while maintaining a financially robust organization.

Skyhook is a Boston-based mobile location services company, founded in 2003, that specializes in hybrid positioning technology. Initially focused on geolocating Wi-Fi access points, the company has since expanded its offerings to include advanced location services that integrate Wi-Fi, GPS, cell towers, IP addresses, and device sensors. In 2015, Skyhook introduced Behavioral Data through an open platform, prioritizing data privacy and security for its advertising and application clients. The company further developed its technology in 2016 with the launch of Precision Location to support wearables and the Internet of Things (IoT), alongside products such as Personas and Context Accelerator, which assist brands in effectively engaging mobile consumers.

Memento specializes in providing enterprise fraud and compliance solutions tailored for credit unions and community banks in North America and Europe. The company’s flagship platform, Security 4.0, integrates data management, fraud analytics, and case management to enable proactive monitoring and real-time alerts, addressing various technological and regulatory challenges. Memento's offerings include tools for monitoring new account fraud across multiple channels and transaction types, as well as solutions for insider threats and deposit account fraud prevention. Additionally, the company provides a suite of services that help smaller financial institutions meet regulatory requirements and combat identity theft. Established in 2002, Memento is headquartered in Concord, Massachusetts, with additional offices in New York, Los Angeles, Milan, London, and Washington, D.C.

Dynatrace, Inc. is a software intelligence company that offers a comprehensive platform for managing and optimizing enterprise cloud applications. The Dynatrace platform enables users to monitor and analyze their entire IT infrastructure, providing insights into application performance, user experience, and operational efficiency. Its product suite includes tools for monitoring various application environments, such as mobile and web applications, as well as network services. Additionally, Dynatrace provides solutions for real user monitoring and synthetic monitoring to ensure application availability and performance. The platform’s advanced capabilities support customers in modernizing IT operations, accelerating software delivery, and enhancing digital experiences. Dynatrace serves a diverse range of industries, including banking, insurance, retail, and manufacturing, and operates globally with a strong presence in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company is headquartered in Waltham, Massachusetts.

aPriori Technologies Inc. specializes in product cost management software solutions for enterprises globally. The company provides an enterprise platform that enables manufacturers and their suppliers to effectively manage and control product costs throughout their organizations. aPriori's software facilitates design for manufacturability (DFM) and design to cost (DTC) insights, promoting collaboration across the product development process. This helps clients make informed decisions regarding design, sourcing, and manufacturing, ultimately reducing product costs and enhancing value. Additionally, aPriori offers a range of services including strategy development, deployment planning, best practice implementation, training, and technical support. Serving sectors such as industrial machinery, aerospace and defense, automotive, and high tech, aPriori was founded in 2003 and is headquartered in Concord, Massachusetts, with an additional office in Belfast, Northern Ireland. The company has established a strategic partnership with QuEST Global Services Pte. Ltd.

Skyhook is a Boston-based mobile location services company, founded in 2003, that specializes in hybrid positioning technology. Initially focused on geolocating Wi-Fi access points, the company has since expanded its offerings to include advanced location services that integrate Wi-Fi, GPS, cell towers, IP addresses, and device sensors. In 2015, Skyhook introduced Behavioral Data through an open platform, prioritizing data privacy and security for its advertising and application clients. The company further developed its technology in 2016 with the launch of Precision Location to support wearables and the Internet of Things (IoT), alongside products such as Personas and Context Accelerator, which assist brands in effectively engaging mobile consumers.

Memento specializes in providing enterprise fraud and compliance solutions tailored for credit unions and community banks in North America and Europe. The company’s flagship platform, Security 4.0, integrates data management, fraud analytics, and case management to enable proactive monitoring and real-time alerts, addressing various technological and regulatory challenges. Memento's offerings include tools for monitoring new account fraud across multiple channels and transaction types, as well as solutions for insider threats and deposit account fraud prevention. Additionally, the company provides a suite of services that help smaller financial institutions meet regulatory requirements and combat identity theft. Established in 2002, Memento is headquartered in Concord, Massachusetts, with additional offices in New York, Los Angeles, Milan, London, and Washington, D.C.

aPriori Technologies Inc. specializes in product cost management software solutions for enterprises globally. The company provides an enterprise platform that enables manufacturers and their suppliers to effectively manage and control product costs throughout their organizations. aPriori's software facilitates design for manufacturability (DFM) and design to cost (DTC) insights, promoting collaboration across the product development process. This helps clients make informed decisions regarding design, sourcing, and manufacturing, ultimately reducing product costs and enhancing value. Additionally, aPriori offers a range of services including strategy development, deployment planning, best practice implementation, training, and technical support. Serving sectors such as industrial machinery, aerospace and defense, automotive, and high tech, aPriori was founded in 2003 and is headquartered in Concord, Massachusetts, with an additional office in Belfast, Northern Ireland. The company has established a strategic partnership with QuEST Global Services Pte. Ltd.

Network Intelligence Corporation provides security information and event management solutions. Its products include enVision that collects and protects data, as well as provides security and compliance analysis, and reporting and alerting solutions; Intelligence Engine software/hardware network security appliances for security information and event management market; and LogSmart Internet Protocol Database, which provides architecture to collect and protect the data from various Internet protocol devices. The company's strategic partners include Microsoft; NetworkAppliance; IBM; EMC2; EDS; Check Point Software Technologies, Ltd.; and Juniper Networks. Network Intelligence Corporation was formerly known as OpenSystems.com, Inc. and changed its name to Network Intelligence Corporation. The company was founded in 1996 and is headquartered in Westwood, Massachusetts. It also has offices in Rancho Santa Margarita, California; Chicago, Illinois; Alpharetta, Georgia; Seabrook, Texas; Arlington, Virginia; Amsterdam, the Netherlands; Paris, France; and London.

ProfitLogic specializes in developing and marketing retail profit optimization software solutions. The company provides a comprehensive suite of tools aimed at enhancing profitability across various retail sectors. Its offerings include software for price optimization, inventory planning, assortment and allocation, in-season inventory management, promotions, and performance assessment. These applications assist retailers in making informed decisions regarding allocation, planning, and pricing to maximize their financial outcomes. Founded in 1983 and based in Cambridge, Massachusetts, ProfitLogic was previously known as Technology Strategy, Inc.

deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.

ProfitLogic specializes in developing and marketing retail profit optimization software solutions. The company provides a comprehensive suite of tools aimed at enhancing profitability across various retail sectors. Its offerings include software for price optimization, inventory planning, assortment and allocation, in-season inventory management, promotions, and performance assessment. These applications assist retailers in making informed decisions regarding allocation, planning, and pricing to maximize their financial outcomes. Founded in 1983 and based in Cambridge, Massachusetts, ProfitLogic was previously known as Technology Strategy, Inc.

deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.

Marathon Technologies Corporation specializes in fault-tolerant and disaster recovery software solutions for both physical and virtual servers. The company’s product lineup includes everRun VM, which safeguards against outages and data loss in Citrix virtual server environments, as well as everRun HA and everRun FT, designed to provide component-level and system-level fault tolerance for Windows server applications, respectively. Additionally, Marathon Technologies offers everRun SplitSite, which ensures geographic fault tolerance to mitigate risks from localized disasters, and everRun CDP & DR, a disaster recovery planning tool that captures and replicates application data to guard against catastrophic failures. Beyond its software offerings, the company also provides consulting, training, and technical support services. Founded in 1993 and headquartered in Littleton, Massachusetts, Marathon Technologies serves a diverse clientele, including broadcast networks, corporate organizations, pharmaceutical companies, casino properties, and midsized businesses.

Solect Energy, located in Hopkinton, Massachusetts, is a prominent player in the commercial-scale solar industry. The company focuses on providing solar energy solutions tailored for businesses, helping them harness renewable energy to reduce costs and enhance sustainability. Solect Energy is known for its expertise in designing, financing, and installing solar energy systems, making it a key partner for organizations looking to transition to solar power.

Cortera, Inc. is a provider of business-to-business analytics and cloud-based risk management solutions, specializing in payment and purchase behavior data for both public and private companies. The company tracks $1.6 trillion in business-to-business purchases across 45 spend categories, delivering insights on 20 million U.S. business locations. Its offerings include Cortera Pulse, which monitors credit risk and key events; Boost, which appends scores and insights about customers and suppliers; and Cortera Decisions, an automated scorecard platform. Additionally, Cortera provides eCredit for credit scoring and collections automation, Cortera Traits for real-time statistical modeling, and Connect, an XML web service for accessing proprietary data. With a focus on helping companies understand their customers and partners, Cortera’s solutions enhance revenue generation, improve sales and marketing effectiveness, and mitigate risk. Founded in 1993 and headquartered in Boca Raton, Florida, the company also has offices in Quincy, Massachusetts, and Bengaluru and Coimbatore, India.